ReviewPhysiological reports2021
Mucin signature as a potential tool to predict susceptibility to COVID-19.
Review in Physiological reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Deciphering Deleterious nsSNPs in MUC16's SEA Domain: Structural and Functional Implications in Cancer Metastasis via Computational Analysis.Journal of cellular and molecular medicine · 2025Article
- Unraveling the relevance of SARS-Cov-2 infection and ferroptosis within the heart of COVID-19 patients.Heliyon · 2024Article
- A Multi-Machine Learning Consensus Model Based on Clinical Features Reveals That Interleukin-10 Derived from Monocytes Leads to a Poor Prognosis in Patients with Coronavirus Disease-2019.Journal of inflammation research · 2024Article
- Article
- Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface.PLoS pathogens · 2023Article
- A non-invasive ultrasensitive diagnostic approach for COVID-19 infection using salivary label-free SERS fingerprinting and artificial intelligence.Journal of photochemistry and photobiology. B, Biology · 2022Article
- Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2022Article
- The COVID-19 pandemic, an environmental neurology perspective.Revue neurologique · 2022Review
- Non-Cellular Layers of the Respiratory Tract: Protection against Pathogens and Target for Drug Delivery.Pharmaceutics · 2022Review
- Targeting mucin hypersecretion in COVID-19 therapy.Future medicinal chemistry · 2022Article
- Effects of Fermented Lingonberry Juice Mouthwash on Salivary Parameters-A One-Year Prospective Human Intervention Study.Dentistry journal · 2022Article
- Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19.PLoS genetics · 2022Article
- Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment.Pharmacology research & perspectives · 2022Review
- MUC22, HLA-A, and HLA-DOB variants and COVID-19 in resilient super-agers from Brazil.Frontiers in immunology · 2022Article
- Mucus targeting as a plausible approach to improve lung function in COVID-19 patients.Medical hypotheses · 2021Article
- A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity.JCI insight · 2021Article
- Gastrointestinal mucosal immunity and COVID-19.World journal of gastroenterology · 2021Review
- Reply to the letter from Dr. Pirjo Pärnänen et al.Physiological reports · 2021Article
- Lingonberry polyphenols: Potential SARS-CoV-2 inhibitors as nutraceutical tools?Physiological reports · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Corona Virus Infectious Disease-19 (COVID-19) pandemic has played havoc on both the global health and economy. It is necessary to find a molecular signature that differentiates between low-risk and high-risk individuals. Pathogens, including viruses of the upper respiratory tract, utilize mucin proteins to enter into host cells. Mucins are critical components of innate immunity and also play important roles in infectious disease progression. Their expression is regulated by different cytokines during infection and inflammation. A comparison of mucin signatures between an asymptomatic versus symptomatic and between patients with mild versus severe symptoms could help identify other important proteins involved in the pathology of this new virus. Recent studies on the pathogenicity of the SARS-CoV-2 have found receptors that help its entry into the cells. In this review, we present an overview of how mucins are connected to the pathogenicity of the virus and propose that studying the glycome and mucin signature may lead to the development of a biomarker in predicting the susceptibility, progression, and response to therapy in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.